CMET Exon 14 Skipping: From the structure to the clinic

Journal of Thoracic Oncology

Volumn 11, Issue 9, 2016, Pages 1423-1432

  Van Der Steen, Nele ^a,b,c   Giovannetti, Elisa ^a,d   Pauwels, Patrick ^b,c   Peters, Godefridus J ^a   Hong, David S ^e   Cappuzzo, Federico ^f   Hirsch, Fred R ^b   Rolfo, Christian ^c,g  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d UNIVERSITY OF PISA   (Italy)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f ISTITUTO TOSCANO TUMORI   (Italy)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Cmet; Exon 14 skipping; NSCLC; Targeted therapies

Indexed keywords

MESENCHYMAL EPITHELIAL TRANSITION FACTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; SCATTER FACTOR RECEPTOR;

CANCER PROGNOSIS; DRUG RESPONSE; EXON SKIPPING; GENETIC VARIABILITY; HUMAN; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; RNA SPLICING; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; EXON; GENETICS; MOLECULARLY TARGETED THERAPY; MUTATION; PHYSIOLOGY;

EXONS; HUMANS; MOLECULAR TARGETED THERAPY; MUTATION; PROTO-ONCOGENE PROTEINS C-MET; RNA SPLICING; SIGNAL TRANSDUCTION;

EID: 84987790603     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/j.jtho.2016.05.005     Document Type: Review

References (86)

1. Garajová I, Giovannetti E, Biasco G, Peters GJ. c-Met as a target for personalized therapy. Transl Oncogenomics. 2015;7:13-31.
2. Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F. Onartuzumab in lung cancer: The fall of Icarus? Expert Rev Anticancer Ther. 2015;15:487-489.
3. Ma PC, Tretiakova MS, Mackinnon AC, et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 2008;47:1025-1037.
4. Lee C-C, Yamada KM. Identification of a noveltype of alternative splicing of a tyrosine kinase receptor. J Biol Chem. 1994;269:19457-19461.
5. Liu X, Jia Y, Stoopler MB, et al. Next-generation sequencing of pulmonary sarcomatoid carcinoma reveals high frequency of actionable MET gene mutations. J Clin Oncol. 2015;34:794-802.
6. Paik PK, Drilon A, Fan P-D, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 2015;5:842-849.
7. Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov. 2015;5: 850-860.
8. Lee J, Ou SI, Lee JM, et al. Gastrointestinal malignancies harbor actionable MET exon 14 deletions. Oncotarget. 2015;6:28211-28222.
9. Bladt F, Riethmacher D, Isenmann S, Aguzzi A, Birchmeier C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature. 1995;376:768-771.
10. Gutiérrez J, Cabrera D, Brandan E. Glypican-1 regulates myoblast response to HGF via Met in a lipid raftdependent mechanism: Effect on migration of skeletal muscle precursor cells. Skelet Muscle. 2014;4:5.
11. Montesano R, Soriano JV, Malinda KM, et al. Differential effects of hepatocyte growth factor isoforms on epithelial and endothelial tubulogenesis. Cell Growth Differ. 1998;9:355-365.
12. Kajiya K, Hirakawa S, Ma B, Drinnenberg I, Detmar M. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J. 2005;24:2885-2895.
13. Borowiak M, Garratt AN, Wüstefeld T, Strehle M, Trautwein C, Birchmeier C. Met provides essential signals for liver regeneration. Proc Natl Acad Sci U S A. 2004;101:10608-10613.
14. Conway K, Price P, Harding KG, Jiang WG. The molecular and clinical impact of hepatocyte growth factor, its receptor, activators, and inhibitors in wound healing. Wound Repair Regen. 2006;14:2-10.
15. Ding S, Merkulova-rainon T, Han ZC. HGF receptor upregulation contributes to the angiogenic phenotype of human endothelial cells and promotes angiogenesis in vitro. Blood. 2003;101:4816-4822.
16. Bauer TW, Somcio RJ, Fan F, Liu W, Johnson M, Lesslie DP, et al. Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther. 2006;5:1676-1682.
17. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316: 1039-1043.
18. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU, Gallick GE. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol. 2007;14:3629-3637.
19. Chen JT, Huang CY, Chiang YY, et al. HGF increases cisplatin resistance via down-regulation of AIF in lung cancer cells. Am J Respir Cell Mol Biol. 2008;38:559-565.
20. Bhardwaj V, Cascone T, Cortez MA, et al. Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy. Cancer. 2013;119: 1768-1775.
21. Qian LW, Mizumoto K, Inadome N, et al. Radiation stimulates HGF receptor/c-Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells. Int J Cancer. 2003;104:542-549.
22. Ponzetto C, Bardelli A, Zhen Z, et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. Cell. 1994;77:261-271.
23. Fixman ED, Fournier TM, Kamikura DM, Naujokas MA, Park M. Pathways downstream of Shc and Grb2 are required for cell transformation by the Tpr-Met oncoprotein. J Biol Chem. 1996;271:13116-13122.
24. Weidner KM, Di Cesare S, Sachs M, Brinkmann V, Behrens J, Birchmeier W. Interaction between Gab1 and the c-Met receptor tyosine kinase is responsible for epithelial morphogenesis. Nature. 1996;384: 173-176.
25. Van Der Steen N, Pauwels P, Gil-Bazo I, et al. cMET in NSCLC: can we cut off the head of the Hydra? From the pathway to the resistance. Cancers. 2015;7: 556-573.
26. Graziani A, Gramaglia D, dalla Zonca P, Comoglio PM. Hepatocyte growth factor/scatter factor stimulates the Ras-guanine nucleotide exchanger. J Biol Chem. 1993;268:9165-9168.
27. Xiao GH, Jeffers M, Bellacosa A, Mitsuuchi Y, Vande Woude GF, Testa JR. Anti-Apoptotic signaling by hepatocyte growth factor/Met via the phosphatidylinositol 3-kinase/Akt and mitogen-Activated protein kinase pathways. Proc Natl Acad Sci U S A. 2001;98:247-252.
28. Zhang Y-W, Wang L-M, Jove R, Vande Woude GF. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis. Oncogene. 2002;21:217-226.
29. Müller M, Morotti A, Ponzetto C. Activation of NF-kB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Mol Cell Biol. 2002;22: 1060-1072.
30. Fan S, Gao M, Meng Q, et al. Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene. 2005;24:1749-1766.
31. Peschard P, Fournier TM, Lamorte L, et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell. 2001;8:995-1004.
32. Parachoniak CA, Luo Y, Abella JV, Keen JH, Park M. GGA3 functions as a switch to promote Met receptor recycling, essential for sustained ERK and cell migration. Dev Cell. 2011;20:751-763.
33. Shibamoto S. Proteolytic processing of the hepatocyte growth factor/scatter receptor by furin. FEBS Lett. 1993;328:25-29.
34. Stamos J, Lazarus RA, Yao X, Kirchhofer D, Wiesmann C. Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor. EMBO J. 2004;23:2325-2335.
35. Kong-Beltran M, Stamos J, Wickramasinghe D. The Sema domain of Met is necessary for receptor dimerization and activation. Cancer Cell. 2004;6:75-84.
36. Kozlov G, Perreault A, Schrag JD, et al. Insights into function of PSI domains from structure of the Met receptor PSI domain. Biochem Biophys Res Commun. 2004;321:234-240.
37. Schiering N, Knapp S, Marconi M, et al. Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a. Proc Natl Acad Sci U S A. 2003;100:12654-12659.
38. Furge KA, Zhang YW, Vande Woude GF. Met receptor tyrosine kinase: Enhanced signaling through adapter proteins. Oncogene. 2000;19:5582-5589.
39. Coolidge CJ, Seely RJ, Patton JG. Functional analysis of the polypyrimidine tract in pre-mRNA splicing. Nucleic Acids Res. 1997;25:888-895.
40. Query CC, McCaw PS, Sharp PA. A minimal spliceosomal complex A recognizes the branch site and polypyrimidine tract. Microbiology. 1997;17:2944-2953.
41. Brow DA. Allosteric cascade of spliceosome activation. Annu Rev Genet. 2002;36:333-360.
42. Makarov EM, Makarova OV, Urlaub H, et al. Small nuclear ribonucleoprotein remodeling during catalytic activation of the spliceosome. Science. 2002;298: 2205-2208.
43. Smith DJ, Query CC, Konarska MM. "Nought may endure but mutability": spliceosome dynamics and the regulation of splicing. Mol Cell. 2008;30:657-666.
44. Busch A, Hertel KJ. Evolution of SR protein and hnRNP splicing regulatory factors. Wiley Interdiscip Rev RNA. 2012;3:1-12.
45. Liu HX, Goodall GJ, Kole R, Filipowicz W. Effects of secondary structure on pre-mRNA splicing: hairpins sequestering the 50 but not the 30 splice site inhibit intron processing in Nicotiana plumbaginifolia. EMBO J. 1995;14:377-388.
46. Buratti E, Baralle FE. Influence of RNA secondary structure on the pre-mRNA splicing process. Mol Cell Biol. 2004;24:10505-10514.
47. Ladomery M. Aberrant alternative splicing is another hallmark of cancer. Int J Cell Biol. 2013;2013.
48. Lee J-H, Gao CF, Lee CC, Kim MD, Vande Woude GF. An alternatively spliced form of Met receptor is tumorigenic. Exp Mol Med. 2006;38:565-573.
49. Lee C-C, Yamada KM. Alternatively spliced Juxtamembrane domain of a tyrosine kinase receptor is a multifunctional regulatory site. J Biol Chem. 1995;270: 507-510.
50. Kong-Beltran M, Seshagiri S, Zha J, et al. Somatic mutations lead to an oncogenic deletion of Met in lung cancer. Cancer Res. 2006;66:283-289.
51. Vigna E, Gramaglia D, Longati P, Bardelli A, Comoglio PM. Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET. Oncogene. 1999;18:4275-4281.
52. Togashi Y, Mizuuchi H, Tomida S, et al. MET gene exon 14 deletion created using the CRISPR/Cas9 system enhances cellular growth and sensitivity to a MET inhibitor. Lung Cancer. 2015;90:590-597.
53. Lee JH, Han SU, Cho H, et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene. 2000;19:4947-4953.
54. Onozato R, Kosaka T, Kuwano H, Sekido Y, Yatabe Y, Mitsudomi T. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol. 2009;4:5-11.
55. Dhanasekaran SM, Alejandro Balbin O, Chen G, et al. Transcriptome meta-Analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes. Nat Commun. 2014;5:5893.
56. Wang Z, Canagarajah BJ, Boehm JC, et al. Structural basis of inhibitor selectivity in MAP kinases. Structure. 1998;6:1117-1128.
57. Liu Y, Bishop A, Witucki L, et al. Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol. 1999;6:671-678.
58. Cui JJ, Tran-dub M, Shen H, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal à epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 2011;54: 6342-6363.
59. Smolen GA, Sordella R, Muir B, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A. 2006;103: 2316-2321.
60. Shaw AT, Ou S-HI, Bang Y-J, et al. Crizotinib in ROS1- rearranged non-small-cell lung cancer. N Engl J Med. 2015;372:683-684.
61. Ou S-HI, Kwak EL, Siwak-Tapp C, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo METamplification. J Thorac Oncol. 2011;6:942-946.
62. Schwab R, Petak I, Kollar M, et al. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. Lung Cancer. 2014;83:109-111.
63. Chi AS, Batchelor TT, Kwak EL, et al. Rapid radiographic and clinical improvement after treatment of a METamplified recurrent glioblastoma with a mesenchymalepithelial transition inhibitor. J Clin Oncol. 2012;30:e30-e33.
64. Okamoto W, Okamoto I, Arao T, et al. Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF- 02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther. 2012;11:1557-1564.
65. Lennerz JK, Kwak EL, Ackerman A, et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 2011;29: 4803-4810.
66. Lacombe D, Burock S, Bogaerts J, Schoeffski P, Golfinopoulos V, Stupp R. The dream and reality of histology agnostic cancer clinical trials. Mol Oncol. 2014;8:1057-1063.
67. Liu X, Wang Q, Yang G, et al. A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-Talk with EGFR and HER-3. Clin Cancer Res. 2011;17:7127-7138.
68. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10:2298-2308.
69. Drilon A, Somwar R, Wagner JP, et al. A novel crizotinibresistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer. Clin Cancer Res. 2015;10:2351-2358.
70. Drilon A, Wang L, Hasanovic A, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 2013;3:630-635.
71. Kollmannsberger CK, Hurwitz H, Vlahovic G, et al. Phase I study of daily administration of MGCD265 to patients with advanced malignancies (study 265-101) [abstract]. J Clin Oncol. 2009;27(suppl):e14525.
72. Morley R, Cardenas A, Hawkins P, et al. Safety of onartuzumab in patients with solid tumors: Experience to date from the onartuzumab clinical trial program. PLoS One. 2015;10:e0139679.
73. Hultberg A, Morello V, Huyghe L, et al. Depleting METexpressing tumor cells by ADCC provides a therapeutic advantage over inhibiting HGF/MET signaling. Cancer Res. 2015;75:3373-3383.
74. Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-met overexpression. J Clin Oncol. 2016;34:721-730.
75. Waqar SN, Morgensztern D, Sehn J. MET mutation associated with responsiveness to crizotinib. J Thorac Oncol. 2015;10:e29-e31.
76. Jenkins RW, Oxnard GR, Elkin S, Sullivan EK, Carter JL, Barbie DA. Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation. Clin Lung Cancer. 2015;16:e101-e104.
77. Lee C, Usenko D, Frampton GM, McMahon C, Ali SM, Weiss J. MET 14 deletion in sarcomatoid non-small-cell lung cancer detected by next-generation sequencing and successfully treated with a MET inhibitor. J Thorac Oncol. 2015;10:e113-e114.
78. Remon J, Morán T, Majem M, et al. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins. Cancer Treat Rev. 2014;40:93-101.
79. Isozaki H, Ichihara E, Takigawa N, et al. Non-small cell lung cancer cells acquire resistance to the ALK inhibitor alectinib by activating alternative receptor tyrosine kinases. Cancer Res. 2015;76:1506-1516.
80. Cepero V, Sierra JR, Corso S, et al. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. 2010;70:7580-7590.
81. Botting GM, Rastogi I, Chhabra G, Nlend M, Puri N. Mechanism of resistance and novel targets mediating resistance to EGFR and c-Met tyrosine kinase inhibitors in non-small cell lung cancer. PLoS One. 2015;10:1-17.
82. Liu K, Song X, Zhu M, Ma H. Overexpression of FGFR2 contributes to inherent resistance to MET inhibitors in MET-Amplified patient-derived gastric cancer xenografts. Oncol Lett. 2015;10:2003-2008.
83. Petti C, Picco G, Martelli ML, et al. Truncated RAF kinases drive resistance to MET inhibition in MET-Addicted cancer cells. Oncotarget. 2015;6:221-233.
84. Taron M, Ichinose Y, Rosell R, et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-Treated chemorefractory lung adenocarcinomas. Clin Cancer Res. 2005;11:5878-5885.
85. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-smallcell lung cancer harbouring ALK gene rearrangement: A retrospective analysis. Lancet Oncol. 2011;12: 1004-1012.
86. Tsuta K, Kozu Y, Mimae T, et al. c-MET/phospho-MET protein expression and MET gene copy number in nonsmall cell lung carcinomas. J Thorac Oncol. 2012;7: 331-339.